Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

PBLA Panbela Therapeutics

Watchlist
0.290
-0.069-19.25%
Trading Session 09/30 12:22 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
0.301
Open
0.250
Turnover
372.81K
Low
0.250
Pre Close
0.359
Volume
1.34M
Market Cap
6.03M
P/E(TTM)
Loss
52wk High
2.400
Shares
20.79M
P/E(Static)
Loss
52wk Low
0.203
Float Cap
4.85M
Bid/Ask %
-95.56%
Historical High
8.800
Shs Float
16.74M
Volume Ratio
1.88
Historical Low
0.203
Dividend TTM
--
Div Yield TTM
--
P/B
-1.24
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
8.03%
Amplitude
14.23%
Avg Price
0.277
Lot Size
1
Float Cap
4.85M
Bid/Ask %
-95.56%
Historical High
8.800
Shs Float
16.74M
Volume Ratio
1.88
Historical Low
0.203
Dividend TTM
--
P/B
-1.24
Dividend LFY
--
Turnover Ratio
8.03%
Amplitude
14.23%
Avg Price
0.277
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
CEO: Simpson C.R.N.P., CRNP, M.S.N., Ph.D., Jennifer K.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top